Harnessing Nanocarriers for Targeted Drug Delivery in Parkinson's Disease: A Pharmacokinetic Perspective

Parkinson's Disease (PD) is one of the most common neurodegenerative disorders, characterized by the death of dopaminergic cells in the substantia nigra part of the brain. Although there are various treatment options, such as levodopa and dopamine agonists, the long-term effectiveness of these therapies is often limited and can cause serious side effects. In this context, the importance of nanocarrier pharmacokinetics in treating PD is becoming increasingly apparent. Nanocarriers, which are drug delivery systems designed to improve the bioavailability and distribution of drugs, offer a potential solution to overcome the challenges in PD treatment. This paper highlights how nanocarriers' physical and chemical characteristics, such as size, shape, and surface modifications, can affect drug pharmacokinetics and therapeutic efficacy. With the ability to cross the blood-brain barrier, nanocarriers can enhance drug accumulation in the target area, reduce systemic side effects, and improve drug stability and solubility. However, challenges related to the toxicity and biocompatibility of nanocarriers still need to be overcome for clinical acceptance. Through collaboration between scientists, clinicians, and the pharmaceutical industry, further research is needed to develop optimal nanocarrier formulations and accelerate the transition from laboratory research to clinical applications. Thus, this paper aims to provide an in-depth insight into the role of nanocarriers in targeted drug delivery for Parkinson's Disease and future clinical implications.